The Role of Interferons in the Pathogenesis of Sjögren’s Syndrome and Future Therapeutic Perspectives
Open Access
- 8 February 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 11 (2), 251
- https://doi.org/10.3390/biom11020251
Abstract
There is a great deal of evidence pointing to interferons (IFNs) as being key cytokines in the pathogenesis of different systemic autoimmune diseases, including primary Sjögren’s syndrome (pSS). In this disease, a large number of studies have shown that an overexpression of type I IFN, the ‘so-called’ type I IFN signature, is present in peripheral blood mononuclear cells, and that this finding is associated with the development of systemic extra-glandular manifestations, and a substantial production of autoantibodies and inflammatory cytokines. In contrast, the absence or a milder expression of type I IFN signature and low level of inflammatory cytokines characterizes patients with a different clinical phenotype, where the disease is limited to glandular involvement and often marked by the presence of widespread pain and depression. The role of type II (IFNγ) in this subset of pSS patients, together with the potentially related activation of completely different immunological and metabolic pathways, are emerging issues. Expression of both types of IFNs has also been shown in target tissues, namely in minor salivary glands where a predominance of type II IFN signature appeared to have a certain association with the development of lymphoma. In view of the role played by IFN overexpression in the development and progression of pSS, inhibition or modulation of IFN signaling has been regarded as a potential target for the therapeutic approach. A number of therapeutic compounds with variable mechanisms of action have been tested or are under consideration for the treatment of patients with pSS.Keywords
This publication has 101 references indexed in Scilit:
- Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseasesProceedings of the National Academy of Sciences of the United States of America, 2012
- Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expressionAnnals Of The Rheumatic Diseases, 2012
- Interferon-stimulated genes and their antiviral effector functionsCurrent Opinion in Virology, 2011
- Signaling and ligand interaction of ILT7: receptor‐mediated regulatory mechanisms for plasmacytoid dendritic cellsImmunological Reviews, 2010
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune DiseasesImmunity, 2009
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Peripheral blood gene expression profiling in Sjögren's syndromeGenes & Immunity, 2009
- Cells with regulatory function of the innate and adaptive immune system in primary Sjögren’s syndromeClinical and Experimental Immunology, 2009
- Association of an IRF5 gene functional polymorphism with Sjögren's syndromeArthritis & Rheumatism, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001